Organogenesis Holdings (ORGO) Return on Capital Employed (2017 - 2026)

Organogenesis Holdings' Return on Capital Employed history runs 10 years deep, the most recent figure standing at 0.53% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 632.0% year-over-year to 0.53% in Q1 2026; TTM through Mar 2026 was 0.53%, a 632.0% increase from a year earlier, with the FY2025 full-year figure at 9.97%, up 1029.0% from the prior year.
• Return on Capital Employed fell to 0.53% in Q1 2026 per ORGO's latest filing, from 9.84% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 16.46% in Q1 2022 and bottomed at 5.79% in Q1 2025.
• The 5-year median for Return on Capital Employed is 3.37% (2024), against an average of 3.33%.
• Across the five-year window, Return on Capital Employed slumped 1852 bps in 2022 and soared 1017 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 5.9% in 2022, then sank by 44 bps to 3.29% in 2023, then tumbled by 110 bps to 0.33% in 2024, then soared by 3127 bps to 9.84% in 2025, then sank by 95 bps to 0.53% in 2026.
• Per Business Quant, the three latest ORGO Return on Capital Employed figures stand at 0.53% (Q1 2026), 9.84% (Q4 2025), and 2.12% (Q3 2025).